Nuclear Receptors as Drug Targets

Author:   Eckhard Ottow (Bayer Schering Pharma AG, Berlin, Germany) ,  Hilmar Weinmann (Bayer Schering Pharma AG, Berlin, Germany) ,  Raimund Mannhold (University of Düsseldorf, Ge) ,  Hugo Kubinyi (University of Heidelberg, Germany)
Publisher:   Wiley-VCH Verlag GmbH
ISBN:  

9783527318728


Pages:   522
Publication Date:   20 August 2008
Format:   Hardback
Availability:   Awaiting stock   Availability explained


Our Price $630.96 Quantity:  
Add to Cart

Share |

Nuclear Receptors as Drug Targets


Overview

Full Product Details

Author:   Eckhard Ottow (Bayer Schering Pharma AG, Berlin, Germany) ,  Hilmar Weinmann (Bayer Schering Pharma AG, Berlin, Germany) ,  Raimund Mannhold (University of Düsseldorf, Ge) ,  Hugo Kubinyi (University of Heidelberg, Germany)
Publisher:   Wiley-VCH Verlag GmbH
Imprint:   Blackwell Verlag GmbH
Dimensions:   Width: 17.80cm , Height: 3.10cm , Length: 24.60cm
Weight:   1.102kg
ISBN:  

9783527318728


ISBN 10:   3527318720
Pages:   522
Publication Date:   20 August 2008
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Hardback
Publisher's Status:   Out of Print
Availability:   Awaiting stock   Availability explained

Table of Contents

Nuclear Receptors as Modern Drug Targets - a Historic Perspective Targeting the Nuclear Receptor - Cofactor Interaction Untangling the Estrogen Receptor Web Subtype Selective Estrogens Estrogen Receptors as Therapeutic Targets in Breast Cancer Progesterone Receptor and Progestines Progesterone Receptor Antagonists Nonsteroidal Tissue Selective Androgen Receptor Modulators The Glucocorticoid Receptor as Target for Classic and Novel Anti-inflammatory Therapy and Novel Glucocorticoid Receptor Ligands Vitamin D Analogs as Modulators of Vitamin D Receptor Action PPARs: Therapeutic Targets for Metabolic Disease and Type 2 Diabetes Retinoids in Clinical Use Nuclear Receptors as Targets in Cardiovascular Diseases NURR77 Family of Nuclear Receptors and its Modulators Induction of Drug Metabolism: The Role of Nuclear Receptors Nuclear Receptor Targeted Screening Libraries and Chemogenomics Approaches

Reviews

With increasing importance attributed to this area, the text is a welcome review of the current field... The quality of the text is good with very readable chapters and many useful original literature references. The book will be clearly valuable for both academic and industrial groups engaged in drug discovery. ( Journal of Medicinal Chemistry , March 2009) This is an excellent book for scientists interested in adding or expanding expertise in nuclear receptor drug discovery to their skill set. The chapters are timely, well referenced into the 2008 literature, and focused on the chemistry of successful and emerging therapeutic small molecules. ( Journal of the American Chemical Society , March 10, 2009) The book is a good reference for medicinal chemists, pharmacologists and those working in the pharmaceutical industry. ( RoSearc h, December 2008)


With increasing importance attributed to this area, the text is a welcome review of the current field... The quality of the text is good with very readable chapters and many useful original literature references. The book will be clearly valuable for both academic and industrial groups engaged in drug discovery. (Journal of Medicinal Chemistry, March 2009) This is an excellent book for scientists interested in adding or expanding expertise in nuclear receptor drug discovery to their skill set. The chapters are timely, well referenced into the 2008 literature, and focused on the chemistry of successful and emerging therapeutic small molecules. (Journal of the American Chemical Society, March 10, 2009) The book is a good reference for medicinal chemists, pharmacologists and those working in the pharmaceutical industry. (RoSearch, December 2008)


Author Information

Eckard Ottow is the head of medicinal chemistry at Schering AG in Berlin (Germany). He studied Chemistry at the University of Hannover (Germany) and received his PhD degree in 1982. He joined Schering AG in 1983, first in the field of endocrinology and later in oncology and CNS. In 2002, he was appointed to his present position as head of medicinal chemistry. He is also a honorary professor at the Technical University of Berlin. Hilmar Weinmann studied Chemistry at the universities of Tubingen and Hannover (Germany). He joined Schering in 1995, where he is currently a department head of Medicinal Chemistry. His main fields of expertise are in oncology, dermatology and gender healthcare.

Tab Content 6

Author Website:  

Countries Available

All regions
Latest Reading Guide

NOV RG 20252

 

Shopping Cart
Your cart is empty
Shopping cart
Mailing List